Yonhap Infomax NewsNov 3
GC Green Cross Co. reported a 26.3% drop in Q3 operating profit to 29.2 billion won, but revenue surged 31.1%, beating market expectations and lifting shares.
#YonhapInfomax #GCGreenCross #OperatingProfit #Q3Earnings #RevenueGrowth #MarketExpectations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88949
GC Green Cross Posts Q3 Operating Profit of 29.2 Billion Won, Down 26.3% Year-on-Year—Beats Market Expectations

GC Green Cross Co. reported a 26.3% drop in Q3 operating profit to 29.2 billion won, but revenue surged 31.1%, beating market expectations and lifting shares.

Yonhap Infomax
Yonhap Infomax NewsAug 1, 2025
GC Green Cross Corp. posted a 55% jump in Q2 operating profit to 27.4 billion won ($21.2 million), with revenue up 19.9%, both figures broadly matching market expectations.
#YonhapInfomax #GCGreenCross #OperatingProfit #Q2Earnings #RevenueGrowth #MarketExpectations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=75193
GC Green Cross Reports Q2 Operating Profit of 27.4 Billion Won, In Line with Market Expectations

GC Green Cross Corp. posted a 55% jump in Q2 operating profit to 27.4 billion won ($21.2 million), with revenue up 19.9%, both figures broadly matching market expectations.

Yonhap Infomax
Yonhap Infomax NewsApr 30, 2025
GC Green Cross expected to turn profitable in Q1 2025, driven by blood product price hikes and vaccine exports, while subsidiaries continue to struggle with losses
#YonhapInfomax #GCGreenCross #Q1Earnings #BloodProducts #VaccineExports #SubsidiaryPerformance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=61085
GC Green Cross Expected to Turn Profitable in Q1 - 'Subsidiaries Still Struggling'

GC Green Cross expected to turn profitable in Q1 2025, driven by blood product price hikes and vaccine exports, while subsidiaries continue to struggle with losses

Yonhap Infomax
Yonhap Infomax NewsApr 16, 2025
GC Green Cross faces financial strain due to recent investments, pins hopes on U.S. sales of immune deficiency drug Alliglo for performance turnaround
#YonhapInfomax #GCGreenCross #Alliglo #FinancialPerformance #USMarketEntry #WorkingCapitalBurden #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=58895
GC Green Cross Suffers Investment Hangover, Will U.S. Drug Sales Be a Tonic?

GC Green Cross faces financial strain due to recent investments, pins hopes on U.S. sales of immune deficiency drug Alliglo for performance turnaround

Yonhap Infomax